P-Glycoprotein-mediated resistance to Hsp90-directed therapy is eclipsed by the heat shock response.
Despite studies that show the antitumor activity of Hsp90 inhibitors, such as geldanamycin (GA) and its derivative 17-allylamino-demethoxygeldanamycin (17-AAG), recent reports indicate that these inhibitors lack significant single-agent clinical activity. Resistance to Hsp90 inhibitors has been previously linked to expression of P-glycoprotein (P-gp) and the multidrug resistant (MDR) phenotype. However, the stress response induced by GA treatment can also cause resistance to Hsp90-targeted therapy. Therefore, we chose to further investigate the relative importance of P-gp and the stress response in 17-AAG resistance. Colony-forming assays revealed that high expression of P-gp could increase the 17-AAG IC(50) 6-fold in cells transfected with P-gp compared with parent cells. A549 cells selected for resistance to GA overexpressed P-gp, but verapamil did not reverse the resistance. These cells also overexpressed Hsp27, and Hsp70 was induced with 17-AAG treatment. When the GA and 17-AAG resistant cells were transfected with Hsp27 and/or Hsp70 small interfering RNA (siRNA), the 17-AAG IC(50) decreased 10-fold compared with control transfected cells. Transfection with siRNA directed against Hsp27, Hsp70, or Hsp27 and Hsp70 also increased sensitivity to EC78, a purine scaffold-based Hsp90 inhibitor that is not a P-gp substrate. We conclude that P-gp may contribute, in part, to resistance to 17-AAG, but induction of stress response proteins, such as Hsp27 and Hsp70, by Hsp90-targeted therapy plays a larger role. Taken together, our results indicate that targeting of Hsp27 and Hsp70 should be exploited to increase the clinical efficacy of Hsp90-directed therapy.
McCollum
Andrea K
AK
Department of Molecular Pharmacology and Experimental Therapeutics, Mayo Clinic College of Medicine, Rochester, Minnesota 55905, USA.
TenEyck
Cynthia J
CJ
Stensgard
Bridget
B
Morlan
Bruce W
BW
Ballman
Karla V
KV
Jenkins
Robert B
RB
Toft
David O
DO
Erlichman
Charles
C
D020168:ATP Binding Cassette Transporter, Subfamily B, Member 1 / Q000037:antagonists & inhibitors / Q000096:biosynthesis / Q000378:metabolism*; D016227:Benzoquinones / Q000494:pharmacology*; D045744:Cell Line, Tumor; D019008:Drug Resistance, Neoplasm; D018841:HSP90 Heat-Shock Proteins / Q000037:antagonists & inhibitors* / Q000096:biosynthesis / Q000378:metabolism; D006360:Heat-Shock Proteins / Q000037:antagonists & inhibitors* / Q000096:biosynthesis / Q000378:metabolism; D018869:Heat-Shock Response; D006801:Humans; D007624:KB Cells; D047029:Lactams, Macrocyclic / Q000494:pharmacology*; D015854:Up-Regulation
D020168:ATP Binding Cassette Transporter, Subfamily B, Member 1; D016227:Benzoquinones; D018841:HSP90 Heat-Shock Proteins; D006360:Heat-Shock Proteins; D047029:Lactams, Macrocyclic; C112765:tanespimycin
FEBS Lett. 1992 Apr 13;301(1):37-40
1360409
Cancer Res. 2006 Nov 15;66(22):10967-75
17108135
Cell. 1997 Jul 11;90(1):65-75
9230303
Mol Endocrinol. 1998 Mar;12(3):342-54
9514152
Pharm Res. 2007 Sep;24(9):1702-12
17457659
Free Radic Biol Med. 1994 Sep;17(3):191-200
7982624
J Biol Chem. 1990 Jan 5;265(1):221-6
1967174
Clin Lymphoma Myeloma. 2006 May;6(6):500-1
16796784
Curr Top Med Chem. 2006;6(11):1183-91
16842155
Mol Endocrinol. 1995 Jun;9(6):670-8
8592513
J Leukoc Biol. 2007 Jan;81(1):15-27
16931602
Mol Cell Biol. 1986 Jun;6(6):2198-206
3023921
Trends Mol Med. 2004 Jun;10(6):283-90
15177193
Cancer Chemother Pharmacol. 1995;36(4):305-15
7628050
Annu Rev Biochem. 2006;75:271-94
16756493
Leukemia. 2005 Jul;19(7):1198-206
15902298
Clin Cancer Res. 2004 Oct 15;10(20):6807-20
15501957
J Pharmacokinet Pharmacodyn. 2003 Jun;30(3):185-219
14571691
Clin Prostate Cancer. 2005 Sep;4(2):138-41
16197617
Cancer Res. 1992 Apr 1;52(7):1721-8
1551101
J Med Chem. 2006 Jan 26;49(2):817-28
16420067
Bioinformatics. 2004 Nov 1;20(16):2778-86
15166021
Proc Natl Acad Sci U S A. 1994 Aug 30;91(18):8324-8
8078881
J Biol Chem. 2002 Nov 29;277(48):45942-8
12324468
Handb Exp Pharmacol. 2006;(172):259-77
16610363
Clin Cancer Res. 2001 Aug;7(8):2228-36
11489796
Cancer Res. 2006 Apr 15;66(8):4191-7
16618741
Cancer Res. 2001 Jan 15;61(2):739-48
11212277
Curr Top Med Chem. 2006;6(11):1193-203
16842156
Clin Cancer Res. 2006 Oct 15;12(20 Pt 1):6087-93
17062684
Proc Natl Acad Sci U S A. 1987 May;84(9):3004-8
3472246
Clin Cancer Res. 2001 Aug;7(8):2155-8
11489788
Math Biosci. 2002 Mar;176(1):35-51
11867082
J Clin Oncol. 2005 Feb 20;23(6):1078-87
15718306
Cancer Res. 2007 Apr 1;67(7):3239-53
17409432
Cancer Sci. 2003 Jan;94(1):15-21
12708468
Mol Pharmacol. 1994 Oct;46(4):677-84
7969046
Invest New Drugs. 2006 Nov;24(6):543-6
16832603
Nature. 1985 Aug 29-Sep 4;316(6031):817-9
2863759
Ann Oncol. 2003 Aug;14(8):1169-76
12881371
J Natl Cancer Inst. 2001 Aug 15;93(16):1246-56
11504770
J Cell Biol. 1998 Nov 16;143(4):901-10
9817749
J Biol Chem. 1997 Sep 19;272(38):23843-50
9295332
Cancer Res. 2005 Nov 15;65(22):10536-44
16288046
J Biol Chem. 2001 Nov 30;276(48):45160-7
11574536
IUBMB Life. 1999 Oct;48(4):429-33
10632574
Endocr Relat Cancer. 2006 Dec;13 Suppl 1:S125-35
17259553
Cell. 1997 Apr 18;89(2):239-50
9108479
Curr Cancer Drug Targets. 2003 Oct;3(5):349-58
14529386
Cancer Chemother Pharmacol. 1998;41(5):417-22
9523739